Drug Trial Radar · NCT05758922
Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
Last checked: Nov 20, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Apr 24, 2023
Primary completion
Apr 19, 2024
Study completion May 5, 2026
Sponsor
- Lead sponsor
- Azafaros B.V.Industry
- Sponsor type
- Industry
- First posted
- Mar 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 2 is a randomized, double-blind, placebo controlled, 12 weeks study with daily oral administration of AZ-3102 aiming to evaluate the safety and pharmacokinetic (PK) profile in GM2 Gangliosidosis and Niemann-Pick type C disease (NP-C) patients. After approval by the country health authorities, a double-blind extension period was proposed to the patients who complete the 12-week study.
Conditions
- GM2 Gangliosidosis
- Niemann-Pick Disease, Type C
Interventions
AZ-3102 (Dose 1)Drug
Pharmaceutical form: capsule Route of administration: oral
PlaceboDrug
Pharmaceutical form: capsule Route of administration: oral
AZ-3102 (Dose 2)Drug
Pharmaceutical form: capsule Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety/tolerability: Incidence and severity of treatment emergent adverse eventsTime frame: Through study completion, up to Week 12
- Assessment of pharmacokinetic (PK) parameters in plasma: CmaxTime frame: Through study completion, up to Week 12
- Assessment of PK parameters in plasma: TmaxTime frame: Through study completion, up to Week 12
- Assessment of PK parameters in plasma: AUC0-24hTime frame: Concentration versus time curve calculated from time 0 to 24 hours (AUC0-24h)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Hospital Pequeno Principe
Curitiba, Brazil
Hospital de Clinicas de Porto Alegre
Porto Alegre, Brazil
Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira
Rio de Janeiro, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.